Last reviewed · How we verify

NCT07351422: TAK-IMPACT

Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis

Recruiting now Last updated 20 January 2026
What this trial tests

trial testing Questionnaire in Takayasu Arteritis in 50 participants. Currently enrolling.

Timeline
1 October 2025
Primary endpoint
15 March 2027
15 March 2027

Quick facts

Lead sponsorUniversity of Edinburgh
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date1 October 2025
Primary completion15 March 2027
Estimated completion15 March 2027
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Edinburgh

Who can join

18 and older, any sex, with Takayasu Arteritis or Takayasu Arteritis (TAK). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for Takayasu Arteritis

Currently open trials in the same condition.

Other University of Edinburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07351422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing